Background:
Chronic rheumatic conditions such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are associated with severe morbidity and significant impairment of patients' health related quality of life (HRQoL). Several treatments are available but not all the patients respond positively to them. Biologic therapies such as anti-TNFα agents are shown to benefit who fail or have partial responses to standard DMARD therapy. Objectives: Within a multicenter stated preferences study (CARA Study), we assessed HRQoL in patients with RA, AS and PsA, and estimated relationship of HRQOL with the different diagnoses, clinical characteristics and biological treatment experience. Methods: Patients with RA, AS, or PsA, who at the time of enrollment were following a treatment (experienced) or received a first prescription (naïve) of treatment with biological drugs were enrolled. Together with preferences data, clinical and HRQOL information was reported. HRQoL was assessed with the recently developed and successfully validated version of the EQ-5D-5L, which allows to obtain a description of health (in 5 domains and 5 levels of severity each), a measure (EQ-VAS) and a valuation (utility) of health. Multiple linear regression analyses were conducted to assess the association between EQ-5D VAS score and the utility with age, sex, diagnosis, treatment experience, years from symptoms onset and years from diagnosis. Results: 513 patients were enrolled (mean±SD =50.0±13.6, 42.5% female). As regards the diagnosis, 33.9% had RA, 34.9% PsA and 31.2% AS. The mean±SD time from the symptoms onset was 10.8±9.4 and from the diagnosis was 8.0±8.2 years. Almost half of the patients (47.4%) were naïve to the biological treatment. Patients reporting severe or extreme problems were: 7.1% in mobility, 3.6% in self-care, 10.3% in usual activities, 18.6% in pain/discomfort, 5.5% in anxiety/depression. The mean±SD of the VAS was 60.4±20.5 and of the utility was 0.773±0.116. From the regression model the VAS and utility are significantly (p<0.05) associated with age, sex and treatment experience (table 1). In particular, the patients being naïve to the treatment with biological drugs had on average significant worse levels of HRQoL than experienced patients, adjusting for the other variables included in the model. Background: Chronic inflammation -the crucial pathogenic mechanism of rheumatoid arthritis is the main cause of accelerated atherosclerosis, insulin resistance and well-known consequences related to it. The conservative treatment of rheumatoid arthritis may provide a significant influence on glucose metabolism. When the duration of rheumatic diseases of administration and dosage of glucocorticoids (GC) are significant predictors of the development of impaired glucose tolerance and diabetes mellitus. Objectives: To study the effect of pulse-therapy (PT) of the GC on the violation of carbohydrate metabolism in patients with rheumatic diseases Methods: The study included 35 patients (7 men, 18 women) with a variety of rheumatic diseases (systemic lupus erythematosus -23, systemic vasculitis -12) between the ages of 18 to 68 years (mean age 42,3±14,43 years) and duration of disease from 6 months to 12 years (mean 3,55±3,36 years). Pulse-therapy of GK included intravenous prednisolone 600-1000 mg per day for 3 consecutive days (course dose of 1800-3000 mg). Oral glucose tolerance test (OGTT) was performed after the course.The first group included patients with a normal result of OGTT (glucose concentration of <7.8 mmol/L at 2 hours after taking 75 g of glucose). There were 23 patients in the first group at the age of 18 to 54 years (mean age 38.0±2.8 years). Patients of the second group level had OGTT was>7.8 mmol/L. This group included 12 people aged from 44 to 61 years (mean age 52,6±8,4 years). All patients underwent the measurement of blood glucose levels prior to PT, 2, 4, 6, 10, 24, 48 and 72 hours and after the PT Results: All patients included in the study, after the PT session there was an increase in blood glucose levels with a peak at 4 hours after the start of administration -12.2±0.82 in the first group, in the second to 21.95±0.25 mmol/l (p<0,05). Normalization of glucose levels in the first group of patients occurred within 1.75±0.18 days (1 to 3), whereas in the second -for 5,0±1,0 (3 to 5; p<0,05). During the OGTT the mean fasting blood glucose levels in patients with the first group was 4.49±0.12 mmol/l, and the second -5,85±0,35 (p<0,05), after 2 hours -6.0±0.21 and 10.0±1.5 mmol/l, respectively (p<0,05 Background: Muscle fatigue is common in sports activities and has been shown to adversely alter proprioception, impair neuromuscular control, and increase the risk of injury. Kinesiotaping has recently gained popularity among sports professionals for its assumed injury prevention and performance enhancement (1). Two studies have reported conflicting findings with respect to the effects of KT on proprioception. Halseth et al reported that KT produced no significant change in the absolute error in ankle joint position sense (2). However, Chang et al reported that KT decreased the force sense error in grip strength measurements among 21 healthy college athletes (3). Thus, the current literature does not provide clear information about the effects of KT on proprioception. Although there are published articles about investigating KT on joint position sense and postural stability, the effects of KT is still unknown after muscle fatigue, to our knowledge. Objectives: There is a lack of literature examining the KT on joint position sense and postural stability following fatigue protocol. Therefore, the aim of this study was to investigate the effects of KT on knee joint position sense and postural stability after muscle fatigue. It was hypothesized that KT applied on quadriceps femoris muscle would partially compensate for the proprioceptive and balance-related deficits caused by muscle fatigue. Methods: Thirty -six healthy subjects were evaluated in the study. Knee joint position sense was assessed by Biodex System Pro 4 during active repositioning tests at the target angles of 30 o , 50 o and 70 o of knee flexion in sagittal plane. Postural stability was assessed by Pedalo Sensamove ® System in antero -posterior and medio -lateral plane. Joint position sense and postural stability were assessed three times: during rest, following the fatigue protocol, and following the taping. The subjects were received a clinically-used fatigue protocol on a cycle ergometer. The Modified Borg's Rate of Perceived Exertion Scale has been used for fatigue determination. Results: Joint position sense and postural stability were significantly decreased following fatigue compared to the condition during rest (p<0.05). However, no significant difference was found in terms of joint position sense and postural stability after taping compared to the condition following fatigue (p>0.05).
Conclusions:
The hypothesis of this study, that KT could partially compensate for the proprioceptive and balance-related deficits induced by muscle fatigue, was not supported. According to the results of our study, we concluded that the subjects do not benefit from the use of KT for compensating joint position sense and postural stability in condition following fatigue. 
Background:
The Health Assessment Questionnaire (HAQ) is an instrument administered to patients to self-report functional status originally in rheumatoid arthritis (RA). In Argentina, it has been translated and validated for RA in 2004. For diffuse SSc, HAQ has been associated to morbidity and mortality. Objectives: To adapt S-HAQ into Spanish and to assess its validity in SSc patients in Argentina. Methods: S-HAQ was translated following a forward-backward translation procedure of the original English version, and transcultural adaptation was performed by a comprehension test reaching the final Spanish version. SSc patients that fulfilled ACR 80 criteria and early Systemic Sclerosis according to Le Roy and Medsger criteria were included. Patients with overlap were excluded. Cronbach's alpha and item-item item-total correlations were used to assess internal consistency. Construction validity was analyzed through factor analysis with Varimax rotation. Continuous variables were compared by t-test, Mann-Whitney or Kruskal-Wallis test, and categorical variables by chi-square or Fisher's test. A value of p<0.05 was considered significant. Results: l9An adapted Argentine-Spanish version of S-HAQ was developed. One hundred patients were surveyed; 84% were female, mean age 54±12.8 years and disease duration 8.8±9.1 years. Limited SSc was more frequent (63%), followed by diffuse SSc (36%). Serologically, 89% were ANA positive, 27% had anti Scl 70 and 41% had anti centromere antibodies. Median Rodnan score (mRSS) was 9.8 (0-40.5) and median activity measured by EUSTAR was 1.25 (0-6). Median S-HAQ was 0.62 (0-2.5), Cronbach's alpha 0.89, and when removing questions one by one the coefficient decreased. Median VAS (visual analogue scale) was 0.57 (0-2.8). Factor analysis identified two factors for the S-HAQ: factor 1: dressing (0.61), arising (0.68), reach (0.63), and personal hygiene (0.70); factor 2: eating (0.68), grip (0.72), walking (0.49), usual activities (0.62). For questions, three factors were identified through VAS: factor 1: overall disease severity (0.63) and gastro-intestinal symptoms (0.57); factor 2: Raynaud's (0.66), digital ulcers (0.56); factor 3: respiratory symptoms (0.43). There was a statistically significant association between higher values of S-HAQ and higher values of mRSS (1.1±0.74 vs. 0.64±0.5 p=0.002) and also with seropositivity for anti-Scl 70 (p=0.003). Higher values of total VAS were associated to female gender (0.75±0.5 vs. 0.49±0.71, p=0.01). There was a significant association between S-HAQ and MEDSGER (p=0.04) and EUSTAR (p=0.03) scores; likewise, between VAS and MEDSGER (p=0.00) and EUSTAR (p=0.00) scores. Conclusions: A Spanish version of S-HAQ was developed, showing an acceptable reliability and validity. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4025 
